Therapeutic Targets Modulation, Inhibition, and Activation

by Botana, Luis M.; Loza, Mabel

• ISBN13: 9780470587195
• ISBN10: 0470587199
• Edition: 1st
• Format: Hardcover
• Copyright: 2012-05-22
• Publisher: Wiley

Summary

This book describes the pharmacology of therapeutically undefined targets and potential applications. In some cases, there are no defined drugs to modulate some of the targets, and in other cases inhibition or activation will render different therapeutic uses. Chapters cover specific biochemical targets like kinases, phosphatases, phosphodiesterases, and potassium channels. Because different diseases can require their own targeting strategies, the book has chapters on the strategies for targeting Alzheimer's, diabetes, pain and inflammation.

Author Biography

Luis M. Botana was Director of the Department of Pharmacology at the University of Santiago de Compostela (USC), Director of the European Union Reference Laboratory for Marine Biotoxins, and scientific advisor to the drug company LCIFGA. The author of 200 papers and 15 patents, Dr. Botana is the editor of several other books, including Phycotoxins: Chemistry and Biochemistry, published by Wiley (2007). Mabel Loza is Professor of Pharmacology at the University of Santiago de Compostela (USC). She created the USEF Drug Screening Platform, with more than ten years of experience in public and private mixed early drug discovery programs.

Table of Contents

Preface	p. vii
Contributors	p. ix
cAMP-Specific Phosphodiesterases: Modulation, Inhibition, and Activation	p. 1
Protease-Activated Receptor 2	p. 37
Voltage-Gated Sodium Channels as Therapeutic Targets	p. 63
Multitarget Drugs for Stabilization of Calcium Cycling and Neuroprotection in Neurodegenerative Diseases and Stroke	p. 123
Oligomerization of G-Protein-Coupled Receptors	p. 201
Sigma 1 Receptor Chaperone: Pharmacology and Therapeutic Perspectives	p. 225
Lipids as New Targets	p. 279
Knowledge Base for Nuclear Receptor Drug Discovery	p. 309
Gene Promoters and Transcription Control Regions as Therapeutic Targets	p. 327
Roles of Glucagon-Like Peptide and Glucose-Dependent lnsolinotropic Polypeptide Hormones in Brain Function and Neurodegeneration	p. 351
Exocytotic Machinery as a Target for the Development of New Drugs for Schizophrenia	p. 375
Targeting Epigenetic Abnormalities in the Brain	p. 409
Rodent Models as Tools for Discovering Novel Therapeutic Targets in the Brain: The Case of Epilepsy	p. 427
New Approaches Applied to Drug Screening	p. 455
Index	p. 477
Table of Contents provided by Ingram. All Rights Reserved.